Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), to include children as young …
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations …
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that the first group of patients has been dosed in a pivotal Phase 2 clinical trial evaluating its QTORIN™ 3.9% rapamycin …
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment Read More WAYNE, PA — Palvella Therapeutics, Inc. has completed its merger with Pieris Pharmaceuticals, Inc., forming a unified company under the name Palvella Therapeutics, Inc. Shares of the newly combined company will …
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments Read More WAYNE, PA — Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations …
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment Read More WAYNE, PA — Palvella Therapeutics, Inc. has appointed Matthew E. Korenberg as its new Chief Financial Officer, a move that underscores the company’s commitment to advancing its rare disease treatment pipeline. …
Palvella Therapeutics Names Matthew Korenberg as New CFO Read More WAYNE, PA — Palvella Therapeutics, Inc. is set to share important research findings at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, taking place from October 24-26, 2024, in Phoenix, …
Palvella Therapeutics to Present Key Findings at Pediatric Dermatology Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. has been awarded up to $2.6 million by the FDA’s Office of Orphan Products Development to support its Phase 3 SELVA trial. This trial investigates …
Palvella Therapeutics Secures $2.6 Million FDA Grant for Phase 3 Trial Read More